HC Wainwright Brokers Increase Earnings Estimates for VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of vTv Therapeutics in a research note issued on Monday, February 2nd. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of $0.96 per share for the quarter, up from their previous estimate of ($0.70). HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($1.28) EPS, FY2027 earnings at ($3.93) EPS, FY2028 earnings at ($3.02) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($1.67) EPS.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th. TD Cowen started coverage on vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating for the company. BTIG Research reissued a “buy” rating and issued a $49.00 price objective (up from $40.00) on shares of vTv Therapeutics in a research report on Tuesday, January 27th. Finally, Roth Mkm started coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.25.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $31.01 on Wednesday. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The company has a 50 day simple moving average of $35.09 and a two-hundred day simple moving average of $25.75. The company has a market capitalization of $122.18 million, a PE ratio of -9.34 and a beta of 0.50.

Institutional Trading of vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP boosted its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.